In terms of established plaques, inhibiting LRP1 in macrophages with blocking antibodies could accelerate plaque regression, potentially alleviating atherosclerosis and related cardiovascular and cerebrovascular complications. The gene discussed is LRP1; the disease is atherosclerosis.